CIK 1534261
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 54.29% | 26 |
| Health Care Providers & Services | 21.02% | 7 |
| Life Sciences Tools & Services | 15.08% | 5 |
| Health Care Equipment & Supplies | 8.61% | 1 |
| Software & IT Services | 1.01% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines, Inc. | Health Care | 18.98% |
| 2 | WGS | GeneDx Holdings Corp. | Health Care | 14.62% |
| 3 | RLAY | Relay Therapeutics, Inc. | Health Care | 10.86% |
| 4 | BLFS | BIOLIFE SOLUTIONS INC | Health Care | 8.61% |
| 5 | LAB | STANDARD BIOTOOLS INC. | Health Care | 6.18% |
| 6 | ILMN | ILLUMINA, INC. | Health Care | 4.95% |
| 7 | GPCR | Structure Therapeutics Inc. | Health Care | 4.29% |
| 8 | TXG | 10x Genomics, Inc. | Health Care | 3.66% |
| 9 | DNLI | Denali Therapeutics Inc. | Health Care | 2.68% |
| 10 | BEAM | Beam Therapeutics Inc. | Health Care | 2.44% |
40/40 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 98.5%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 10% of book weight classified — the grid is NOT representative of the whole book.
Classified: 10.3% of book weight (6/40 names) · unclassified 89.7%: RVMD, WGS, RLAY, BLFS, LAB, GPCR, TXG, DNLI, BEAM, GH +24 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | RVMDREVOLUTION MEDICINES INC | 2,577,333 | $251M | 19.0% | HOLD |
| 2 | WGSGENEDX HOLDINGS CORP | 3,007,164 | $193M | 14.6% | HOLD |
| 3 | RLAYRELAY THERAPEUTICS INC | 14,418,574 | $143M | 10.9% | ADD 11% |
| 4 | BLFSBIOLIFE SOLUTIONS INC | 5,957,165 | $114M | 8.6% | HOLD |
| 5 | LABSTANDARD BIOTOOLS INC | 88,783,856 | $82M | 6.2% | HOLD |
| 6 | ILMNILLUMINA INC | 530,000 | $65M | 4.9% | TRIM −12% |
| 7 | GPCRSTRUCTURE THERAPEUTICS INC | 1,175,000 | $57M | 4.3% | HOLD |
| 8 | TXG10X GENOMICS INC | 2,275,000 | $48M | 3.7% | ADD 63% |
| 9 | DNLIDENALI THERAPEUTICS INC | 1,840,000 | $35M | 2.7% | HOLD |
| 10 | BEAMBEAM THERAPEUTICS INC | 1,350,000 | $32M | 2.4% | TRIM −16% |
| 11 | GHGUARDANT HEALTH INC | 315,000 | $29M | 2.2% | TRIM −17% |
| 12 | NGNENEUROGENE INC | 1,420,361 | $29M | 2.2% | ADD 10% |
| 13 | ALNYALNYLAM PHARMACEUTICALS INC | 75,000 | $25M | 1.9% | HOLD |
| 14 | MAZEMAZE THERAPEUTICS INC | 758,857 | $23M | 1.7% | HOLD |
| 15 | SRRKSCHOLAR ROCK HLDG CORP | 350,000 | $17M | 1.3% | ADD 35% |
| 16 | AGMBAGOMAB THERAPEUTICS NV | 1,550,000 | $16M | 1.2% | NEW |
| 17 | HIMSHIMS & HERS HEALTH INC | 700,000 | $15M | 1.1% | ADD 82% |
| 18 | TSHATAYSHA GENE THERAPIES INC | 3,250,000 | $15M | 1.1% | ADD 117% |
| 19 | QGENQIAGEN NV | 360,000 | $14M | 1.1% | NEW |
| 20 | TEMTEMPUS AI INC | 294,127 | $13M | 1.0% | HOLD |
| 21 | SEPNSEPTERNA INC | 553,268 | $13M | 1.0% | HOLD |
| 22 | GRALGRAIL INC | 230,000 | $12M | 0.9% | NEW |
| 23 | PRMEPRIME MEDICINE INC | 3,167,175 | $11M | 0.8% | HOLD |
| 24 | PSNLPERSONALIS INC | 1,600,000 | $10M | 0.8% | NEW |
| 25 | DGXQUEST DIAGNOSTICS INC | 50,000 | $10M | 0.7% | HOLD |
| 26 | VCYTVERACYTE INC | 276,308 | $9M | 0.7% | HOLD |
| 27 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 450,000 | $8M | 0.6% | NEW |
| 28 | NTLAINTELLIA THERAPEUTICS INC | 355,000 | $5M | 0.3% | NEW |
| 29 | IRONDISC MEDICINE INC | 65,000 | $4M | 0.3% | NEW |
| 30 | MRNAMODERNA INC | 75,000 | $4M | 0.3% | NEW |
| 31 | ANLADLAI NORTYE LTD | 538,461 | $4M | 0.3% | NEW |
| 32 | GLUEMONTE ROSA THERAPEUTICS INC | 186,014 | $3M | 0.2% | ADD 116% |
| 33 | ABSIABSCI CORPORATION | 973,260 | $3M | 0.2% | HOLD |
| 34 | IPSCCENTURY THERAPEUTICS INC | 1,228,190 | $3M | 0.2% | HOLD |
| 35 | BBOTBRIDGEBIO ONCOLOGY THERAPEUTIC | 282,312 | $3M | 0.2% | HOLD |
| 36 | CTNMCONTINEUM THERAPEUTICS INC | 148,333 | $2M | 0.1% | HOLD |
| 37 | PACBPACIFIC BIOSCIENCES CALIF IN | 723,767 | $955,372 | 0.1% | TRIM −83% |
| 38 | RXRXRECURSION PHARMACEUTICALS IN | 165,323 | $507,542 | 0.0% | HOLD |
| 39 | TNYATENAYA THERAPEUTICS INC | 361,969 | $250,627 | 0.0% | HOLD |
| 40 | DNAGINKGO BIOWORKS HOLDINGS INC | 36,493 | $223,702 | 0.0% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| RVMDREVOLUTION MEDICINES INC | 3.7M | 3.7M | 2.9M | 2.6M | 2.6M | 2.6M | $251M |
| WGSGENEDX HOLDINGS CORP | 3.5M | 3.5M | 3.5M | 3.0M | 3.0M | 3.0M | $193M |
| RLAYRELAY THERAPEUTICS INC | 8.9M | 9.1M | 11.4M | 11.3M | 13.0M | 14.4M | $143M |
| BLFSBIOLIFE SOLUTIONS INC | 8.7M | 8.7M | 7.7M | 6.7M | 6.0M | 6.0M | $114M |
| LABSTANDARD BIOTOOLS INC | 71.3M | 76.1M | 76.1M | 77.6M | 88.8M | 88.8M | $82M |
| ILMNILLUMINA INC | 750K | 595K | 645K | 525K | 600K | 530K | $65M |
| GPCRSTRUCTURE THERAPEUTICS INC | 700K | 700K | 1.2M | 1.6M | 1.2M | 1.2M | $57M |
| TXG10X GENOMICS INC | — | — | — | — | 1.4M | 2.3M | $48M |
| DNLIDENALI THERAPEUTICS INC | 990K | 990K | 890K | 890K | 1.8M | 1.8M | $35M |
| BEAMBEAM THERAPEUTICS INC | 1.3M | 1.4M | 1.4M | 1.6M | 1.6M | 1.4M | $32M |
| GHGUARDANT HEALTH INC | 350K | 250K | 100K | 100K | 380K | 315K | $29M |
| NGNENEUROGENE INC | 1.3M | 1.3M | 1.3M | 1.3M | 1.3M | 1.4M | $29M |
| ALNYALNYLAM PHARMACEUTICALS INC | 140K | 120K | 82K | 55K | 75K | 75K | $25M |
| MAZEMAZE THERAPEUTICS INC | — | 946K | 759K | 759K | 759K | 759K | $23M |
| SRRKSCHOLAR ROCK HLDG CORP | — | — | — | — | 260K | 350K | $17M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
